“Triple positive” early breast cancer: an observational multicenter retrospective analysis of outcome
Patrizia Vici(Istituti di Ricovero e Cura a Carattere Scientifico), Filippo Montemurro(Roche (Switzerland)), Loretta D’Onofrio(Università Campus Bio-Medico), Marcello Maugeri‐Saccà(National Cancer Institute), Laura Pizzuti, Laura Iezzi(Ospedale SS. Annunziata), Angelo Fedele Scinto, Luca Moscetti(Ospedale di Belcolle), Stefania Gori(Ospedale Sacro Cuore Don Calabria), Domenico Sergi(National Cancer Institute), Clara Natoli(Kliniken Essen-Mitte), Teresa Gamucci, Ruggero De Maria(Università Cattolica del Sacro Cuore), Paolo Marchetti(Istituto Dermopatico dell'Immacolata), Editta Baldini(IMT School for Advanced Studies Lucca), Domenico Corsi(Ospedale San Carlo), Maddalena Barba(National Cancer Institute), Lucia Da Ros(University of Ferrara), Valentina Sini(Ospedale di Santo Spirito), Antonio Frassoldati(Italian Oncology Group of Clinical Research), Isabella Sperduti(San Gallicano Hospital), Federica Tomao(Sapienza University of Rome), Francesco Giotta(Istituto Tumori Bari), Alessandra Cassano, Ilaria Bertolini(Azienda Ospedaliera Universitaria Pisana), Michelangelo Russillo(National Cancer Institute), Diana Giannarelli(Agostino Gemelli University Polyclinic), Daniele Santini(Policlinico Umberto I), Andrea Michelotti(University of Pisa), Valentina Rossi(University of Naples Federico II), Lucia Mentuccia(Accademia di Belle Arti di Frosinone), Luigi Di Lauro, Maria Luisa Basile(Policlinico Umberto I)
Cited by 43
Related Papers
Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018
|Cell Death and Differentiation|2018|6.6k
Identification and expansion of the tumorigenic lung cancer stem cell population
|Cell Death and Differentiation|2007|1.7k
Primary Tumor Response to Preoperative Chemoradiation With or Without Oxaliplatin in Locally Advanced Rectal Cancer: Pathologic Results of the STAR-01 Randomized Phase III Trial
|Journal of Clinical Oncology|2011|763
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|743
Galectins and their ligands: amplifiers, silencers or tuners of the inflammatory response?
|Trends in Immunology|2002|530